Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients
Status:
Unknown status
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
Contrast-Induced Nephropathy (CIN) can occur when patients with pre-existing kidney problems
undergo procedures that use iodinated contrast media, such as cardiac catheterizations.
RenalGuard Therapy was developed to enable the patient to clear the contrast out of their
kidney before it can do significant damage. This study aims to enroll patients with increased
risk of developing CIN who are scheduled for a cardiovascular catheterization. Patients will
be randomized to either RenalGuard therapy or standard therapy.
Phase:
Phase 3
Details
Lead Sponsor:
CardioRenal Systems, Inc. PLC Medical Systems, Inc.